Scarica l'app Stockscreener
0.9429
4.20%
-0.0413
Dopo l'orario di chiusura:
.95
0.0071
+0.75%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SCYX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.9842
Aprire:
$0.98
Volume 24 ore:
365.41K
Relative Volume:
0.68
Capitalizzazione di mercato:
$74.91M
Reddito:
$20.60M
Utile/perdita netta:
$-8.61M
Rapporto P/E:
-6.8277
EPS:
-0.1381
Flusso di cassa netto:
$-5.28M
1 W Prestazione:
-4.35%
1M Prestazione:
+6.19%
6M Prestazione:
+49.43%
1 anno Prestazione:
-2.70%
Intervallo 1D:
$0.93
$0.9999
Intervallo di 1 settimana:
$0.93
$1.03
Portata 52W:
$0.565
$1.31
Scynexis Inc Stock (SCYX) Company Profile
Nome
Scynexis Inc
Settore
Telefono
201-884-5485
Indirizzo
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX vs TAK, ZTS, TEVA, HLN, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.9429 | 78.19M | 20.60M | -8.61M | -5.28M | -0.1381 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-22 | Iniziato | Guggenheim | Buy |
| 2021-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-11 | Aggiornamento | Needham | Hold → Buy |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-10 | Iniziato | ROTH Capital | Buy |
| 2017-05-09 | Downgrade | Needham | Buy → Hold |
| 2017-03-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-20 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-07 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2016-08-17 | Iniziato | Guggenheim | Buy |
| 2016-08-09 | Reiterato | Needham | Buy |
| 2016-08-09 | Aggiornamento | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | Iniziato | Brean Capital | Buy |
| 2015-12-29 | Iniziato | WBB Securities | Speculative Buy |
| 2015-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2015-06-10 | Iniziato | Needham | Buy |
| 2014-05-29 | Iniziato | Canaccord Genuity | Buy |
| 2014-05-29 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Scynexis Inc Borsa (SCYX) Ultime notizie
MSN Money - MSN
SCYX (SCYNEXIS) posts 87.3 percent Q4 2025 EPS beat, while shares dip slightly in today’s trading. - Newser
Scynexis Ongoing Deadline Alert - TMX Newsfile
SCYNEXIS (SCYX) registers 87M shares for resale after private placement - Stock Titan
Scynexis Shareholder Alert - TMX Newsfile
SCYX Forecast, Price Target & Analyst Ratings | SCYNEXIS INC (NASDAQ:SCYX) - ChartMill
SCYNEXIS (NASDAQ: SCYX) seeks approval for equity plan boost and higher authorized shares - Stock Titan
Scynexis Deadline Reminder - TMX Newsfile
MSN - MSN
3.01M-share position reported for SCYNEXIS (SCYX) by CVI/Heights - Stock Titan
SCYNEXIS (NASDAQ: SCYX) seeks approval for reverse stock split - Stock Titan
SCYX SCYNEXIS Inc. reports 87.3 percent Q4 2025 EPS beat, shares climb 5.71 percent in today’s trading. - Cổng thông tin điện tử tỉnh Tây Ninh
SCYNEXIS (NASDAQ: SCYX) seeks shareholder votes on plan increase and authorized shares - Stock Titan
SCYNEXIS Director Steven Gilman Announces Board Retirement - TipRanks
Steven C. Gilman to Retire from SCYNEXIS Board at 2026 Annual Meeting - TradingView
Director Steven Gilman to retire from SCYNEXIS (NASDAQ: SCYX) Board - Stock Titan
SCYNEXIS, Inc. Announces Retirement of Director Steven C. Gilman - marketscreener.com
SCYNEXIS (SCYX) Stock: Distribution Signals (Spikes) 2026-04-18Viral Momentum Stocks - Xã Thanh Hà
SCYNEXIS (NASDAQ: SCYX) asks shareholders to approve 1-for-5–1-for-10 reverse split - Stock Titan
Squadron Capital Management LLC Acquires 7,608,695 Shares in SCY - GuruFocus
Ideas Watch: Is SCYNEXIS Inc benefiting from innovation trendsGap Down & Real-Time Buy Zone Alerts - baoquankhu1.vn
SCYNEXIS INC (NASDAQ:SCYX) Combines Minervini Trend Template with High-Growth Momentum Fundamentals - ChartMill
Aug Patterns: Is SCYNEXIS Inc stock trending bullish2026 Reactions & High Win Rate Trade Tips - baoquankhu1.vn
Squadron Fund holds 9.6% of SCYNEXIS (NASDAQ: SCYX) - Stock Titan
Great Point Partners (SCYX) reports 9.99% ownership, joint filing details - Stock Titan
United StatesMintz Advises On SCYNEXIS’ Up To $92.2 Million Private Placement - Mondaq
Scynexis CEO Angulo Gonzalez buys $100k in shares By Investing.com - Investing.com Australia
Scynexis CEO Angulo Gonzalez buys $100k in shares - Investing.com
SCYNEXIS (SCYX) CEO joins private placement, adds stock and warrants - Stock Titan
SCYNEXIS, Inc. (SCYX) stock price, news, quote and history - Yahoo Finance UK
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD TherapeuticsSlideshow (NASDAQ:SCYX) 2026-04-01 - Seeking Alpha
SCYNEXIS Acquires PXL-770 (SCY-770) to Advance Innovative ADPKD Therapy with Phase 2 Trial Planned for 2026 - Minichart
SCYNEXIS raises $40 million in private placement financing By Investing.com - Investing.com South Africa
SCYNEXIS acquires SCY-770 for rare kidney disease treatment By Investing.com - Investing.com South Africa
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease - TipRanks
SCYX Should I Buy - Intellectia AI
SCYNEXIS (SCYX) extends cash runway to 2029 with $40M PIPE and SCY-770 ADPKD deal - Stock Titan
SCYNEXIS Announces $40 Million Private Placement to Fund SCY-770 Development for Rare Kidney Disease - Minichart
Why did SCYX stock jump 10% in pre-market today? - MSN
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline - TipRanks
SCYNEXIS Raises $40 Million in Strategic Private Placement - TipRanks
SCYX to Acquire Poxel's PXL770, Targeting ADPKD Treatment Market - GuruFocus
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - BioSpace
SCYX: Acquisition of SCY-770 enables rapid entry into rare renal disease with strong clinical and commercial prospects - TradingView
Scynexis Inc Azioni (SCYX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.67%
2.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):